ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 0624

Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis

Dong-Jin Park1, Hyemin Jeong2, Sung-Eun Choi3, Ji-Hyoun Kang2 and Shin-Seok Lee4, 1Chonnam National University Medical School and Hospital, Gwangju, South Korea, 2Chonnam National University Hospital, Gwangju, South Korea, 3Chonnam National University Medical School & Hospital, Gwangju, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea

Meeting: ACR Convergence 2024

Keywords: Damage Index, Inflammation, Lupus nephritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Conflicting studies have reported varying associations between tubulointerstitial inflammation (TII), tubulointerstitial damage (TID), and the long-term outcomes of lupus nephritis (LN), due to analyzing them separately despite their frequent coexistence. To address these discrepancies and explore the combined prognostic value of TII and TID, we aimed to investigate whether coexisting tubulointerstitial lesions predict chronic kidney disease (CKD) progression in LN patients.

Methods: Data from 175 LN patients, collected at the time of renal biopsy, were analyzed. Patients were stratified into two groups based on the presence or absence of coexisting TII/TID. Uni- and multivariable Cox proportional hazard regression models were utilized to identify independent risk factors for CKD in LN patients.

Results: Of 175 patients, 110 (62.9%) exhibited coexisting TII/TID, while 65 (37.1%) did not. Patients with coexisting TII/TID tended to be older and presented with higher levels of ESR and 24-hour proteinuria, as well as lower levels of eGFR and hemoglobin compared to those without coexisting TII/TID. Over a mean follow-up period of 89.9 months, CKD and end-stage renal disease occurred more frequently in patients with coexisting TII/TID. Notably, the presence of coexisting TII/TID was associated with a higher risk of CKD progression, with adjusted hazard ratios of 2.667 (95% CI: 1.333, 5.335, P = 0.006) for all LN patients, 3.265 (95% CI: 1.451, 7.345, P = 0.004) for those with class III, IV, and V LN, and 3.045 (95% CI: 1.289, 7.195, P = 0.011) for those with class III, IV, V LN, and eGFR ≥ 30 mL/min/1.73 m².

Conclusion: LN patients with coexisting TII/TID are at a heightened risk of kidney function deterioration at LN onset and subsequent development of CKD over the long term.


Disclosures: D. Park: None; H. Jeong: None; S. Choi: None; J. Kang: None; S. Lee: None.

To cite this abstract in AMA style:

Park D, Jeong H, Choi S, Kang J, Lee S. Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/coexisting-tubulointerstitial-inflammation-and-damage-is-a-risk-factor-for-chronic-kidney-disease-in-patients-with-lupus-nephritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coexisting-tubulointerstitial-inflammation-and-damage-is-a-risk-factor-for-chronic-kidney-disease-in-patients-with-lupus-nephritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology